FDA Grants Priority Review to Rucaparib for BRCA1/2-Positice mCRPC

The FDA granted priority review to rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

Lascia un commento